MarketCap
Facebook
X
Telegram
Mustang Bio Net Income | MBIO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Mustang Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.92 M | -15.8 M | -51.6 M | -77.5 M | -66.4 M | -60 M | -46.4 M | -30.7 M | -31.3 M | -12.7 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.92 M | -77.5 M | -39.4 M |
Quarterly Net Income Mustang Bio
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.07 M | -955 K | -468 K | -762 K | -153 K | -1.41 M | -8.2 M | -5.19 M | -10.1 M | -16.2 M | -16.7 M | - | -19 M | -19.1 M | -19.8 M | - | -17 M | -14.4 M | -15 M | - | -13 M | -14.6 M | -11.9 M | -16.2 M | -10.2 M | -10.4 M | -9.61 M | -11.8 M | -7.52 M | -5.09 M | -6.28 M | -15.6 M | -6.94 M | -5.53 M | -3.22 M | -8.75 M | -1.87 M | -1.13 M | -903 K | -911 K | -716 K | -579 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -153 K | -19.8 M | -8.41 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Bristol-Myers Squibb Company
BMY
|
7.05 B | $ 61.27 | -0.36 % | $ 125 B |  USA |
 |
OncoSec Medical Incorporated
ONCS
|
-34.2 M | - | 31.87 % | $ 1.61 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Novan
NOVN
|
-31.3 M | - | -24.84 % | $ 2.64 M | USA |
 |
Benitec Biopharma
BNTC
|
-45.5 M | $ 8.67 | 0.23 % | $ 404 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-76.1 M | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
-241 M | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-16.9 M | - | - | $ 13.6 B | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-141 M | - | - | $ 29.6 M | USA |
 |
Atossa Therapeutics
ATOS
|
-34.8 M | $ 2.49 | -4.23 % | $ 21.4 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-41 M | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
-65.2 M | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-43.6 M | - | - | $ 728 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-10.3 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Rubius Therapeutics
RUBY
|
-180 M | - | -33.55 % | $ 7.81 M | USA |
 |
Burford Capital Limited
BUR
|
62.6 M | $ 3.21 | -4.19 % | $ 703 M |  Britain |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
-3.59 M | - | -1.38 % | $ 46.8 M | USA |
 |
Revance Therapeutics
RVNC
|
-324 M | - | - | $ 309 M | USA |
 |
Epizyme
EPZM
|
-251 M | - | - | $ 249 M | USA |
 |
Aprea Therapeutics
APRE
|
-12.6 M | $ 0.45 | -12.27 % | $ 2.94 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Forward Pharma A/S
FWP
|
-1.89 M | - | -0.75 % | $ 18.7 M |  Danmark |
 |
PDS Biotechnology Corporation
PDSB
|
-7.56 M | $ 1.07 | -4.05 % | $ 49.6 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
-57.2 M | - | - | $ 4.55 M |  Irlanda |
 |
NGM Biopharmaceuticals
NGM
|
-142 M | - | - | $ 127 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Regulus Therapeutics
RGLS
|
-46.4 M | - | - | $ 155 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Titan Pharmaceuticals
TTNP
|
-4.71 M | - | -3.76 % | $ 3.47 M | USA |
 |
NeuBase Therapeutics
NBSE
|
-4.37 M | - | -1.56 % | $ 12.3 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
-162 M | $ 6.61 | 3.12 % | $ 575 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-10.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-152 M | - | - | $ 58.1 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Scopus BioPharma
SCPS
|
-11.6 M | - | -48.37 % | $ 3.71 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-21.2 M | - | -60.05 % | $ 125 K | USA |
 |
Theratechnologies
THTX
|
-31.7 M | - | - | $ 83.9 M | Canada |
 |
Capricor Therapeutics
CAPR
|
-105 M | $ 5.81 | -2.11 % | $ 270 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-70.8 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-7.26 M | - | - | $ 521 M | USA |
 |
Axcella Health
AXLA
|
-81.2 M | - | -16.42 % | $ 249 M | USA |
 |
scPharmaceuticals
SCPH
|
-85.1 M | - | - | $ 218 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B | USA |
 |
Athersys
ATHX
|
-72.5 M | - | 3.77 % | $ 22.4 M | USA |
 |
Tyme Technologies
TYME
|
-23.6 M | - | 8.07 % | $ 54 M | USA |
 |
Catalyst Biosciences
CBIO
|
9.88 M | $ 12.6 | -1.72 % | $ 1.13 B | USA |
 |
Inozyme Pharma
INZY
|
-102 M | - | - | $ 207 M | USA |